Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 115


Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, Yarasheski K, Berzins B, Owens S, Forand J, Evans S, Murphy R.

J Antimicrob Chemother. 2009 May;63(5):998-1005. doi: 10.1093/jac/dkp071. Epub 2009 Mar 19.


Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).

Tebas P, Zhang J, Yarasheski K, Evans S, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG).

J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):193-200.


Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA; Mitochondrial Toxicity (MITOX) Study Group.

JAMA. 2002 Jul 10;288(2):207-15.


Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.


Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.

Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams E.

Cochrane Database Syst Rev. 2014 May 22;5:CD004772. doi: 10.1002/14651858.CD004772.pub4. Review.


A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.

Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, Leen C, Reilly G; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK.

AIDS. 2006 Oct 24;20(16):2043-50.


Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team.

PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.


Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.


Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.

Martin A, Smith DE, Carr A, Ringland C, Amin J, Emery S, Hoy J, Workman C, Doong N, Freund J, Cooper DA; Mitochondrial Toxicity Study Group.

AIDS. 2004 Apr 30;18(7):1029-36.


Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults.

Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, Gatell JM, Cahn P, Chaves R.

AIDS. 2008 Nov 12;22(17):2313-21. doi: 10.1097/QAD.0b013e328315a7a5.


Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.

Gerschenson M, Kim C, Berzins B, Taiwo B, Libutti DE, Choi J, Chen D, Weinstein J, Shore J, da Silva B, Belsey E, McComsey GA, Murphy RL.

J Antimicrob Chemother. 2009 Jun;63(6):1244-50. doi: 10.1093/jac/dkp100. Epub 2009 Mar 25.


Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.

Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD004772. doi: 10.1002/14651858.CD004772.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;5:CD004772.


Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.

Feeney ER, van Vonderen MG, Wit F, Danner SA, van Agtmael MA, Villarroya F, Domingo P, Capeau J, Reiss P, Mallon PW; MEDICLAS, NECATT study groups.

AIDS. 2012 Nov 13;26(17):2165-74. doi: 10.1097/QAD.0b013e328358b279.


Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.

Bernardino JI, Pulido F, Martinez E, Arrizabalaga J, Domingo P, Portilla J, Ocampo A, Muñoz J, Torres R, Arribas JR; GESIDA-6008-KRETA Study Group.

J Antimicrob Chemother. 2013 Jun;68(6):1373-81. doi: 10.1093/jac/dks540. Epub 2013 Feb 5.


Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.

Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugyenyi P, Gibb DM, Gilks CF; DART/NORA trial teams.

HIV Med. 2010 May;11(5):334-44. doi: 10.1111/j.1468-1293.2009.00786.x. Epub 2010 Feb 3.


Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

van Vonderen MG, van Agtmael MA, Hassink EA, Milinkovic A, Brinkman K, Geerlings SE, Ristola M, van Eeden A, Danner SA, Reiss P; MEDICLAS study group.

PLoS One. 2009 May 21;4(5):e5647. doi: 10.1371/journal.pone.0005647.


HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.

Martin A, Moore CL, Mallon PW, Hoy JF, Emery S, Belloso WH, Phanuphak P, Ferret S, Cooper DA, Boyd MA; Second-Line Study Team.

PLoS One. 2013 Oct 30;8(10):e77138. doi: 10.1371/journal.pone.0077138. eCollection 2013.


A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.


Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team.

AIDS. 2009 Jun 1;23(9):1109-18. doi: 10.1097/QAD.0b013e32832b4377.


Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Negredo E, Miró O, Rodríguez-Santiago B, Garrabou G, Estany C, Masabeu A, Force L, Barrufet P, Cucurull J, Domingo P, Alonso-Villaverde C, Bonjoch A, Morén C, Pérez-Alvarez N, Clotet B; MULTINEKA Study Group.

Clin Infect Dis. 2009 Sep 15;49(6):892-900. doi: 10.1086/605440.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk